The science behind the ArteraAI Prostate Test
ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient’s clinical data. The AI combines this information to predict whether a patient will benefit from hormone therapy and estimate long-term outcomes.
The algorithm has been developed using large sets of data, from thousands of patients and tens of thousands of pathology slide images, and has been clinically validated with multiple Phase 3 randomized trials.
Predicting therapeutic benefit from hormone therapy
The only predictive ST-ADT tool recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate CancerReferenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer V.3.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed March 12, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Spratt DE, et al. NEJM Evidence. 2023;2(8):EVIDoa2300023.
NCCN, National Comprehensive Cancer Network.
Current method
Today’s standard of care for men with intermediate localized prostate cancer is to treat them with short-term androgen-deprivation therapy in combination with radiation therapy (RT + ST-ADT), but only 34% actually need it. Side effects include medical castration.
Overall Analysis Population (RTOG 9408)
Shows marginal benefit to including short-term hormone therapy in combination with radiation therapy.
Hazard ratio: 0.64 (95% CI, 0.45-0.90, P = 0.01)
n = 1719 patients studied
With ArteraAI Prostate Test
The AI identifies the 34% of patients who may greatly benefit from short-term hormone therapy.
AI Biomarker Negative
Identify patients who may not need short-term
hormone therapy.
Hazard ratio: 0.92 (95% CI, 0.59-1.43, P = 0.71)
n = 1046 patients studied
AI Biomarker Positive
Identify patients who may greatly benefit from short-term
hormone therapy.
Hazard ratio: 0.34 (95% CI, 0.19-0.63, P < 0.001)
n = 673 patients studied
First-ever predictive and prognostic test
ArteraAI Prostate Test is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer.
Robust model validation
Multiple Phase 3 randomized trials with up to 15-year follow-up were used to develop and validate prognostic and predictive AI models.
Representing diverse populations
African American men are disproportionately affected, making up 16.3% of prostate cancer patients. ArteraAI’s models were developed using clinical trial data comprising approximately 20% African American men.Roach et al. 2022. Prostate cancer risk in African American men evaluated via digital histopathology multi-modal deep learning models developed on NRG Oncology phase III clinical trials. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 108-108. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.108
Ordering is easy with ArteraAI
The ArteraAI Prostate Test is a laboratory developed testTesting is performed by ArteraAI, located at 6800 Southpoint Pkwy Suite 950, Jacksonville, Florida 32216. The ArteraAI Prostate Test was developed and its performance characteristics were determined by ArteraAI. This Laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ‘88) as qualified to perform high-complexity clinical laboratory testing. This test is used for clinical purposes and should not be regarded as investigational or for research. This test has not been cleared or approved by the U.S. Food and Drug Administration. that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL.
-
The ArteraAI Prostate Test is intended to help clinicians determine the therapeutic benefit for patients who have been diagnosed with localized prostate cancer who have not yet received androgen deprivation therapy.
-
Yes! You can visit the ArteraAI Test Report page to explore each section of the report to better understand the results.
-
Currently, the ArteraAI Prostate Test may be ordered in 48 states. ArteraAI is currently not accepting orders from California or New York. ArteraAI is actively pursuing licensing in these states and will post future updates to certification status on this website.
-
After you reach out to us, a member of our Customer Success team will set up an account in the ArteraAI Portal to enable order submission.
-
No. Ordering of the ArteraAI Prostate Test is limited to clinicians whose license and scope of practice allows them to order the test. However, we encourage patients to share information about ArteraAI with their doctor.
-
Using the ArteraAI Prostate Test, results can be shared within 2-3 days after receipt of the patient’s specimen.
-
The out-of-pocket cost for the ArteraAI Prostate Test will be based on the patient’s insurance plan. If the patient is covered by Medicare Plan B, they should have zero out-of-pocket costs for the ArteraAI Prostate Test. If the patient is covered by private insurance, financial liability will be subject to the terms of their plan taking into consideration copays, coinsurance and deductibles. Patients should contact support@artera.ai for additional questions about their estimated out-of-pocket liability for the test.
Order the ArteraAI
Prostate Test for
your patient.
Start your order
